Endonovo Therapeutics, Inc. (ENDV) financial statements (2020 and earlier)

Company profile

Business Address 6320 CANOGA AVENUE
WOODLAND HILLS, CA 91367
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5548583796656895
Cash and cash equivalents5548583796656895
Receivables1181033107
Other undisclosed current assets2330  212121
Total current assets:395866938268999123
Noncurrent Assets
Property, plant and equipment77678910
Intangible assets, net (including goodwill)3,3683,5303,6913,8534,0154,1774,338
Intangible assets, net (excluding goodwill)3,3683,5303,6913,8534,0154,1774,338
Total noncurrent assets:3,3753,5373,6973,8604,0234,1854,348
TOTAL ASSETS:3,4144,1233,7664,2424,7114,2844,471
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,4741,2091,1779433,1803,0702,992
Accounts payable346281199157   
Accrued liabilities 928978786   
Interest and dividends payable1,128      
Other undisclosed accounts payable and accrued liabilities    3,1803,0702,992
Debt6,9386,5526,0166,0546,9675,8631
Deferred compensation liability2,3872,3452,2762,246   
Derivative instruments and hedges, liabilities7,0678,1733,8684,4267,0573,1203,819
Due to related parties195230260270270270270
Other undisclosed current liabilities1,7631,7061,6381,539  5,191
Total current liabilities:19,82520,21415,23615,47917,47412,32312,273
Noncurrent Liabilities
Long-term debt and lease obligation   32   
Long-term debt, excluding current maturities   32   
Other undisclosed noncurrent liabilities1551551551231,3201,077821
Total noncurrent liabilities:1551551551551,3201,077821
Total liabilities:19,98020,36915,39115,63418,79313,40013,094
Temporary equity, carrying amount1,7631,7061,6381,5391,165922666
Stockholders' equity
Stockholders' equity attributable to parent, including:(16,566)(16,247)(11,625)(11,392)(14,082)(9,116)(8,623)
Preferred stock0000000
Common stock83735243383634
Common stock, share subscribed but unissued, subscriptions receivable(2)(2)(2)(2)(2)(2) 
Common stock, value, subscriptions      (2)
Additional paid in capital30,62229,54626,35224,18722,88421,90421,149
Deferred compensation equity(1,000)(977)(940)    
Accumulated deficit(47,270)(45,864)(38,027)(35,620)(37,002)(31,054)(29,803)
Other undisclosed stockholders' equity attributable to parent1,0009779400000
Other undisclosed stockholders' equity(1,763)(1,706)(1,638)(1,539)(1,165)(922)(666)
Total stockholders' equity:(18,329)(17,953)(13,263)(12,931)(15,246)(10,038)(9,289)
TOTAL LIABILITIES AND EQUITY:3,4144,1233,7664,2424,7114,2844,471

Income statement (P&L) ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Revenues5463454221137
Cost of revenue(9)(30)(8)(8)(4)(1) 
Gross profit:4533373417127
Operating expenses(1,336)(1,008)(850)(1,066)(1,052)(829)(1,282)
Operating loss:(1,291)(975)(813)(1,032)(1,035)(817)(1,275)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(115)(6,863)(1,593)2,414(4,913)(434)656
Interest and debt expense1113(5)850144115
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(11)(13)5(8)(50)(144)(115)
Net income (loss) available to common stockholders, diluted:(1,406)(7,838)(2,406)1,382(5,948)(1,251)(619)

Comprehensive Income ($ in thousands)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Net income (loss):(1,406)(7,838)(2,406)1,382(5,948)(1,251)(619)
Comprehensive income (loss), net of tax, attributable to parent:(1,406)(7,838)(2,406)1,382(5,948)(1,251)(619)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: